地库碘铵 | 382-82-1

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: 地库碘铵
• 英文名称: Dicolinium iodide
• 英文别名: diethyl-methyl-[2-(1,1,6-trimethylpiperidin-1-ium-2-carbonyl)oxyethyl]azanium;diiodide
• CAS: 382-82-1
• 化学式: C16H34I2N2O2
• 分子量: 540.26
• InChiKey: UHMKISIRZFDJRU-UHFFFAOYSA-L

计算性质

• 辛醇/水分配系数(LogP)：
  -3.96
• 重原子数：
  22
• 可旋转键数：
  7
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.94
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  4

文献信息

• Diagnostic/therapeutic agents
  申请人：Klaveness Jo

  公开号：US20050002865A1

  公开（公告）日：2005-01-06

  Targetable diagnostic and/or therapeutically active agents, e.g. ultrasound contrast agents, comprising a suspension in an aqueous carrier liquid of a reporter comprising gas-containing or gas-generating material, said agent being capable of forming at least two types of binding pairs with a target.

  可定位的诊断和/或治疗活性剂，例如超声对比剂，包括悬浮在水载体液中的报告物，该报告物包含含气体或生成气体的材料，该剂能够与目标形成至少两种结合对。
• Verfahren zur Herstellung von Proteinen
  申请人：Dr. Karl Thomae GmbH

  公开号：EP0315782A2

  公开（公告）日：1989-05-17

  Methode zur Steigerung der Produktion von Protein, insbeson­dere t-PA in Kulturen von diesem Protein produzierenden Zel­len, wobei man der Zellkultur eine Substanz, die die Produk­tion des Protein induziert, zusetzt, dadurch gekennzeichnet, daß man als Protein-induzierende Substanz Thioglykolsäure, Thiodiglykolsäure, L-Cystein, Glutathion, Butyrylcholinbro­mid, Butyrylcholinchlorid, Nonactinsäure, Furanfettsäure, Ascorbinsäure, Aphidicolin, 6-Hydroxy-4,6-Dimethyl-3- hep­ten-2-on, Fusarinsäure, Mevalonsäure, Trans-anhydromevalon­säure, Anhydromevalonsäurelacton, cis-Anhydromevalonsäure­lacton, D-α-hydroxysubstituierte (C₃ oder C₄) aliphati­sche Mono- oder Di-carbonsäure oder deren Salze verwendet.

  在产生蛋白质（特别是 t-PA）的细胞培养物中增加蛋白质（特别是 t-PA）产量的方法，其中在细胞培养物中加入一种诱导蛋白质产量的物质，其特征在于所用的蛋白质诱导物质是硫代乙醇酸、硫代二乙醇酸、L-半胱氨酸、谷胱甘肽、溴化丁酰胆碱、氯化丁酰胆碱、壬乳酸、呋喃脂肪酸、抗坏血酸、蚜虫啉、6-羟基-4,6-二甲基-3-庚烯-2-酮、扶桑花青素、丁酰胆碱氯化物、壬酸、呋喃脂肪酸、抗坏血酸、蚜虫胆碱、6-羟基-4,6-二甲基-3-庚烯-2-酮、扶桑酸、甲羟戊酸、反式-无水丙酮酸、D-α- 羟基取代（C₃ 或 C₄）脂肪族单羧酸或二羧酸或其盐。
• Methods and devices for the treatment of ocular conditions
  申请人：deJuan Eugene

  公开号：US20060110428A1

  公开（公告）日：2006-05-25

  Featured is a method for instilling one or more bioactive agents into ocular tissue within an eye of a patient for the treatment of an ocular condition, the method comprising concurrently using at least two of the following bioactive agent delivery methods (A)-(C): (A) implanting a sustained release delivery device comprising one or more bioactive agents in a posterior region of the eye so that it delivers the one or more bioactive agents into the vitreous humor of the eye; (B) instilling (e.g., injecting or implanting) one or more bioactive agents subretinally; and (C) instilling (e.g., injecting or delivering by ocular iontophoresis) one or more bioactive agents into the vitreous humor of the eye.
• METHODS AND DEVICES FOR THE TREATMENT OF OCULAR CONDITIONS
  申请人：deJuan Eugene

  公开号：US20110159073A1

  公开（公告）日：2011-06-30

  Featured is a method for instilling one or more bioactive agents into ocular tissue within an eye of a patient for the treatment of an ocular condition, the method comprising concurrently using at least two of the following bioactive agent delivery methods (A)-(C): (A) implanting a sustained release delivery device comprising one or more bioactive agents in a posterior region of the eye so that it delivers the one or more bioactive agents into the vitreous humor of the eye; (B) instilling (e.g., injecting or implanting) one or more bioactive agents subretinally; and (C) instilling (e.g., injecting or delivering by ocular iontophoresis) one or more bioactive agents into the vitreous humor of the eye.
• US6261537B1
  申请人：——

  公开号：US6261537B1

  公开（公告）日：2001-07-17